Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates.
The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with high mortality in humans and nonhuman primates. Among the most promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses an individual filovirus...
Saved in:
Main Authors: | Chad E Mire (Author), Andrew D Miller (Author), Angela Carville (Author), Susan V Westmoreland (Author), Joan B Geisbert (Author), Keith G Mansfield (Author), Heinz Feldmann (Author), Lisa E Hensley (Author), Thomas W Geisbert (Author) |
---|---|
Format: | Book |
Published: |
Public Library of Science (PLoS),
2012-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.
by: Chad E Mire, et al.
Published: (2013) -
A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
by: David Safronetz, et al.
Published: (2015) -
A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge.
by: Courtney Woolsey, et al.
Published: (2022) -
The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials
by: Ellen Suder, et al.
Published: (2018) -
Transcriptional correlates of disease outcome in anticoagulant-treated non-human primates infected with ebolavirus.
by: Sara Garamszegi, et al.
Published: (2014)